Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

fast track appraisal

Can Cinderella save us?

NICE gets tough on antibiotic prescribers

Watchdog says the threat of antimicrobial resistance must be tackled now

- PMLiVE

Biomedical Catalyst funding ‘must continue’, says BIA

UKbiotech body warns against re-appearance of funding 'valley of death'

Daiichi Sankyo logo

Daiichi’s new anticoagulant recommended by NICE

Lixiana nears NHS funding approval for certain patients with atrial fibrillation

- PMLiVE

BMS launches Opdivo for lung cancer in UK

Drug to be called ‘Nivolumab BMS’ in the country

National Institute for Health and Care Excellence NICE logo

Another NICE no for AZ’s new ovarian cancer drug

Cost watchdog wants more information for Lynparza

ABPI Scotland appoints Sandra Auld as director

Takes over from Andrew-Powrie Smith who left to join EPFIA this year

- PMLiVE

Access to new hep C treatments put under the spotlight

NICE plans to restrict use of BMS’ Daklinza follow funding delay for Gilead's Sovaldi

- PMLiVE

NHS England proposes handing CDF remit to NICE

Comes after a difficult two years for the silo budget

- PMLiVE

EFPIA’s Richard Torbett to move to the ABPI

Will take up commercial role at UK pharma bodyat the end of the month

- PMLiVE

NICE backs Bayer’s Eylea in diabetic eye condition

TheInstitute also recommends Allergan's Ozurdex in final guidance

- PMLiVE

Pharma must ‘create new social contract’

New task force established in UK to assess public’s view of the value and risk of medicines

National Institute for Health and Care Excellence NICE logo

NICE no for new eye disease drug

Institute says ‘gaps and uncertainties’ in the treatment’s evidence directed its decision

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links